MedTrace Logo

Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis

NCT01669447 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-08-21

No results posted yet for this study

Summary

Significant difference in the parameter settings of early optical coherence tomography (OCT spectal domain) in patients with subfoveal neovascular membrane realacionada age after treatment with a single intravitreal injection of Lucentis.

Conditions

  • Degeneration of Macula and Posterior Pole

Interventions

BIOLOGICAL

ranibizumab

Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320. To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium. Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment.

Sponsors & Collaborators

  • Osias Francisco de Souza

    lead OTHER

Principal Investigators

  • NICOLLE ALMEIDA, GRADUATE · CENTRO MÉDICO OFTALMOLÓGICO

  • Osias Souza, PI · CENTRO MEDICO OFTALMOLÓGICO

  • Claudia Viana, graduate · Centro Medico Oftalmológico

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01669447 on ClinicalTrials.gov